ArticleNeuro-oncology2017

A phase I trial of the MEK inhibitor selumetinib (AZD6244) in pediatric patients with recurrent or refractory low-grade glioma: a Pediatric Brain Tumor Consortium (PBTC) study.

Anuradha Banerjee et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.